EPM2A

Across TCGA pan-cancer cohorts, EPM2A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EPM2A data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EPM2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EPM2A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where EPM2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.988	0.806	.002	71	view →
PDAC	DFS	Tertile	All	0.117	0.605	.011	15	view →
LUAD	DFS	Quartile	III,IV	0.356	1.000	.013	10	view →
UCEC	OS	Quartile	II,III,IV	0.398	1.000	.027	8	view →
GBM	DFS	Quartile	All	0.496	0.280	.032	5	view →
HNSC	DFS	Median	IV	0.760	0.530	.031	5	view →
LSCC	OS	Tertile	All	0.732	0.926	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EPM2A–CCRCC (OS)

Open the CCRCC breakdown →